Raymond James Financial, Inc. vs Relay Therapeutics Inc. Common Stock — how do they compare? Raymond James Financial, Inc. trades at $158.14 (market cap $30.25B), while Relay Therapeutics Inc. Common Stock trades at $17.5 (market cap $3.94B). The key difference: Raymond James Financial, Inc. is far larger — about 7.7× Relay Therapeutics Inc. Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.37% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| RJF | RLAY | |
|---|---|---|
Market Cap | $30.25B | $3.94B |
Volume | 1,288,635 | 3,432,928 |
Sector | Financials | Health |
52-Week High | $181.18 | $20.75 |
52-Week Low | $140.89 | $6.03 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $24.12B | $3.06B |
Dividend Yield | 1.37% | — |
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $158.6, down 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.14, and maintains solid fundamentals including a P/E of 13.71 and ROE of 18.48%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical weakness and high investing cash outflows pose risks. Revenue growth and margin stability support long-term value, though market volatility and expense pressures remain concerns for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →